Premium
Calcitonin as a marker for bronchogenic cancer. A prospective study
Author(s) -
Silva Omega L.,
Broder Lawrence E.,
Doppman John L.,
Snider Richard H.,
Moore Charles F.,
Cohen Martin H.,
Becker Kenneth L.
Publication year - 1979
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197908)44:2<680::aid-cncr2820440240>3.0.co;2-j
Subject(s) - medicine , calcitonin , bronchogenic carcinoma , prospective cohort study , cancer , thyroid , thyroid cancer , oncology , carcinoma , gastroenterology
A prospective study was done of serum calcitonin (HCT) levels in 61 patients with bronchogenic cancer. Initially, 52% of patients had hypercalcitonemia. Hypercalcitonemia was not confined to patients with any particular histologic type. Seventy‐eight percent of those with high calcitonin remained normocalcemic. There was no correlation between high calcitonin levels and osseous metastases. Selective thyroid venous sampling delineated two types of hypercalcitonemia: thyroidal and ectopic. To date, the ectopic type has been associated with the small cell bronchogenic carcinoma. High initial calcitonin levels decreased significantly in 75% of patients on antitumor therapy. In 13 evaluable patients calcitonin levels mirrored clinical status changes 67% of the time. Calcitonin may be a useful marker to assess the results of therapy in patients with bronchogenic cancer. Cancer 44:680‐684, 1979.